ELDN — Eledon Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1404281 ·
Last close
$1.98
Market Cap
$167.23M
52W High
$4.49
52W Low
$1.35
ADV30
909,232
Next earnings
—
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -21,672,000 -3,933,000 106,639,000 6,882,000 75,843,000
Jun 2026 0 — -22,869,000 -31,630,000 126,094,000 6,803,000 93,081,000
Mar 2026 0 — -21,181,000 -39,025,000 146,667,000 6,152,000 101,903,000
Dec 2025 0 — -21,484,000 -10,447,000 169,009,000 22,808,000 87,924,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-73,857,000
Investing CF
$21,136,000
Financing CF
$53,783,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.94
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-471,858,000
Inventory
—
Receivables
$427,000
ST Investments
$81,953,000
EBIT TTM
$-84,604,000
Pretax Income TTM
$-98,526,000
Interest Exp TTM
—
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -83,251,000 -45,617,000 169,009,000 87,924,000 81,085,000 -62,341,000
Dec 2024 0 -70,577,000 -36,184,000 177,405,000 114,959,000 62,446,000 -47,271,000
Dec 2023 0 -43,000,000 -116,537,000 89,066,000 81,858,000 7,208,000 -39,527,000
Dec 2022 0 -39,780,000 -87,966,000 92,793,000 8,610,000 84,183,000 -28,424,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
$-98,561,000
OpCashFlow TTM
—
Assets (Latest)
$126,094,000
Forward EPS
$-0.77

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $2.03 · call volume: 11 · put volume: 70

Peers — same industry

TickerNameMarket CapLastDaily %
ORMP ORAMED PHARMACEUTICALS INC. $168.29M $3.87 —
KRRO Korro Bio, Inc. $169.10M $12.32 —
IFRX InflaRx N.V. $169.47M $1.15 —
YARW Yarrow Bioscience, Inc. $163.04M $14.21 —
PYXS Pyxis Oncology, Inc. $172.24M $1.44 —

News headlines (Yahoo Finance, 1h cache)

Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-12 21:35 · Yahoo
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology
2026-10-26 11:00 · Yahoo
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
2026-10-05 20:05 · Yahoo
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
2026-09-09 11:00 · Yahoo
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-13 20:05 · Yahoo
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
2026-06-25 11:00 · Yahoo
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared wit
2026-06-22 11:00 · Yahoo
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 20:05 · Yahoo
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
2026-05-27 11:55 · Yahoo
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
2026-06-08 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.